Form 4: Twist Bioscience Officer Sells Shares for Tax Obligations

A Twist Bioscience executive sold 521 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary of Twist Bioscience Corp, reported a transaction on August 21, 2025.
• The transaction involved the sale of 521 shares of Common Stock at a price of $25.964 per share.
• The sale was a 'sell to cover' transaction, mandated by the Issuer's equity incentive plans to satisfy tax withholding obligations upon the vesting of Restricted Stock Units.
• This sale was not a discretionary trade by the Reporting Person.
• Following the reported transaction, Dennis Cho beneficially owns 103,306 shares of Common Stock directly.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary 'sell to cover' for tax purposes related to RSU vesting, which is a neutral event for the company's stock performance.

Positives

• The transaction indicates the vesting of Restricted Stock Units (RSUs), which is a form of compensation for the executive and suggests continued employment and performance.

Negatives

• The sale of shares, while non-discretionary, reduces the executive's direct ownership in the company by 521 shares.

Management Comments

• The sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.

Industry Context

This filing is a routine insider transaction report (Form 4) and does not provide broader industry context or trends. 'Sell to cover' transactions are common across all industries for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: The sale of 521 shares is a minor, routine event and is unlikely to have a significant impact on the overall share price or shareholder value.
• Employees: The vesting of RSUs is a positive for the executive, representing earned compensation.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary 'sell to cover' transaction by an executive to satisfy tax obligations upon RSU vesting. Such transactions do not reflect a change in management's confidence in the company and are not typically considered a material factor for investment decisions. Therefore, the filing itself does not warrant a change in investment recommendation, suggesting a 'hold' position based solely on this information.

Keywords

Twist Bioscience, TWST, Insider Transaction, Form 4, Restricted Stock Units, RSU Vesting, Sell to Cover, Tax Withholding, Dennis Cho